Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 47, Issue 11, 2006, Pages 2380-2387

  Herrera, L ^a   Stanciu Herrera, C ^a   Morgan, C ^b   Ghetie, V ^c   Vitetta, E S ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Childhood leukemia; Immunotherapy; Immunotoxins; Monoclonal antibodies; Pre B ALL

Indexed keywords

DAUNORUBICIN; IMMUNOTOXIN; IMMUNOTOXIN CD19; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HD37 DGRTA; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL TIME;

ANIMALS; ANTIBODIES; ANTIGENS, CD19; CELL LINE, TUMOR; DNA; HUMANS; IMMUNOTOXINS; LEUKEMIA, B-CELL, ACUTE; MALE; MICE; MICE, SCID; SURVIVAL RATE;

EID: 33751101580     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600821989     Document Type: Article

References (30)

1. Niemeyer, C and Sallan, S.(1998) Acute Lymphoblastic Leukemia. In Hematology of Infancy and Childhood. (pp. 1245-1285). Philadelphia: WB Saunders Company.
2. Hoelzer, D and Gokbuget, N and Ottmann, O and Pui, C and Relling, M and Appelbaum, F and (2002) Acute lymphoblastic leukemia Hematology (Am Soc Hematol Educ Program), pp. 162-192.
3. Dillman, R. (2002) Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma J Clin Oncol, 20, pp. 3545-3557.
4. Chen, Y and Tang, Y and Shen, H and Song, H and Yang, S and Shi, S and (2004) The expression of CD19 in 210 cases of childhood acute leukemia and its significance Zhonghua Er Ke Za Zhi, 42, pp. 188-191.
5. Czuczman, M and Dodge, R and Stewart, C and Frankel, S and Davey, S and Powell, B and (1999) Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia Group B study 8364 Blood, 93, pp. 3931-3939.
6. Uckun, F and Jaszcz, W and Ambrus, J and Fauci, A and Gajl-Peczalska, K and Song, C and (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins Blood, 71, pp. 13-29.
7. Scheuermann, R and Racila, E. (1995) CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy Leuk Lymphoma, 18, pp. 385-397.
8. Ghetie, M and May, R and Till, M and Uhr, J and Ghetie, V and Knowles, P and (1988) Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy Cancer Res, 48, pp. 2610-2617.
9. Dorken, B and Moldenhauer, G and Schwartz, R and Pezzutto, A. (1983) B cell differeniation antigens identified by monoclonal antibodies Immunobiology, 165, pp. 253-254.
10. Ghetie, M and Tucker, K and Richardson, J and Uhr, J and Vitetta, E. (1992) The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin Blood, 80, pp. 2315-2320.
11. Herrera, L and Yarbrough, S and Ghetie, V and Aquino, D and Vitetta, E. (2003) Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins Leukemia, 17, pp. 334-338.
12. Sievers, E. (2003) Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg) Blood Cells Mol Dis, 31, pp. 7-10.
13. Mulford, D and Jurcic, J. (2004) Antibody-based treatment of acute myeloid leukaemia Exp Opin Biol Ther, 4, pp. 95-105.
14. Gokbuget, N and Hoelzer, D. (2004) Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects Ann Hematol, 83, pp. 201-205.
15. Blattman, J and Greenberg, P. (2004) Cancer immunotherapy: A treatment for the masses Science, 305, pp. 200-205.
16. Kaleem, Z and Crawford, E and Pathan, M and Jasper, L and Covinsky, M and Johnson, L and (2003) Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data Arch Pathol Lab Med, 127, pp. 42-48.
17. Ludwig, W and Reiter, A and Loffler, H and Gokbuget, N and Hoelzer, D and Riehm, H and (1994) Immunophenotypic features of childhood and adult acute lymphoblastic leukemia [ALL]: Experience of the German multicentre trials ALL-BFM and GMALL Leuk Lymphoma, 13(Suppl 1), pp. 71-76.
18. Pulczynski, S and Boesen, A and Jensen, O. (1993) Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: An immunofluorescence and immunoelectron microscopy study Blood, 81, pp. 1549-1557.
19. Stone, M and Sausville, E and Fay, J and Headlee, D and Collins, R and Figg, W and (1996) A phase I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma Blood, 88, pp. 1188-1197.
20. Ghetie, M and Tucker, K and Richardson, J and Uhr, J and Vitetta, E. (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail Blood, 84, pp. 702-707.
21. Messmann, R and Vitetta, E and Headlee, D and Senderowicz, A and Figg, W and Schindler, J and (2000) A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain [dgA] and IgG-RFB4-dgA (Combotox) in patients with refractory CD19[+], CD22[+] B cell lymphoma Clin Cancer Res, 6, pp. 1302-1313.
22. Vitetta, E and Stone, M and Amlot, P and Fay, J and May, R and Till, M and (1991) Phase I immunotoxin trial in patients with B-cell lymphoma Cancer Res, 51, pp. 4052-4058.
23. May, R and Vitetta, E and Moldenhauer, G and Dorken, B. (1986) Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins Cancer Drug Deliv, 3, pp. 261-272.
24. Ghetie, M and Podar, E and Gordon, B and Pantazis, P and Uhr, J and Vitetta, E. (1996) Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma Int J Cancer, 68, pp. 93-96.
25. Herrera, L and Farah, R and Pellegrini, V and Aquino, D and Sandler, E and Buchanan, G and (2000) Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro Leukemia, 14, pp. 853-858.
26. Jansen, B and Kersey, J and Jaszcz, W and Gunther, R and Nguyen, D and Chelstrom, L and (1993) Effective immunochemotherapy of human t[4;11] leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide Leukemia, 7, pp. 290-297.
27. Liu, C and Lambert, J and Teicher, B and Blattler, W and O'Connor, R. (1996) Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs Blood, 87, pp. 3892-3898.
28. Ek, O and Gaynon, P and Zeren, T and Chelstrom, L and Myers, D and Uckun, F. (1998) Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase Leuk. Lymphoma, 31, pp. 143-149.
29. O'Connor, R and Liu, C and Ferris, C and Guild, B and Teicher, B and Corvi, C and (1995) Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors Blood, 86, pp. 4286-4294.
30. Shah, S and Halloran, P and Ferris, C and Levine, B and Bourret, L and Goldmacher, V and (1993) Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models Cancer Res, 53, pp. 1360-1367.